Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK10 | O94804 | 3/20 | 0.34 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327335 | 0.87 | STK10 (0.34) | STK10SLKRORCMAPK14TRPA1 | |
| SCHEMBL23348208 | 0.85 | BRAF (0.38) | MAPK14SCN9APTGS2 | |
| SCHEMBL20568466 | 0.84 | STK10 (0.34) | STK10SLKRORCSCN9A | |
| SCHEMBL29750721 | 0.81 | TRPA1 (0.34) | STK10SLKRORCTRPA1SCN9A | |
| SCHEMBL20568482 | 0.71 | BRAF (0.36) | SCN9APTGS2 | |
| SCHEMBL20569068 | 0.69 | PDE3B (0.35) | SCN9APTGS2 | |
| SCHEMBL29750710 | 0.67 | SCN9A (0.35) | MAPK14SCN9ANR1H2NR1H3PTGS2 | |
| SCHEMBL23348173 | 0.62 | GCGR (0.39) | MAPK14 | |
| SCHEMBL514295 | 0.60 | NPSR1 (0.53) | — | |
| SCHEMBL23348207 | 0.60 | GCGR (0.46) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | STK10 2434/4885SLK 2656/4885RORC 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.